Earnings: AudioCodes reports rise in profit

Net income rose to $3.9m., or nine cents a share, from $2.6m., or six cents, a year ago, the company said in a statement.

By AVI KRAWITZ
February 1, 2006 07:01
1 minute read.
audio codes 88

audio codes 88. (photo credit: )

AudioCodes Ltd., which develops technology for Internet phone calls, said profit grew in the fourth quarter because of its ties with telecommunications companies that raised spending on advanced networks. Net income rose to $3.9 million, or nine cents a share, from $2.6m., or six cents, a year ago, the company said in a statement. Revenue climbed to $30.6m. from $25.2m. Results were in line with the mean forecast of three analysts surveyed by Bloomberg News. Full-year profit more than doubled to $13.4m., or 31 cents a diluted share, from $5m., or 12 cents, in the previous year. Revenue rose to $115.8m. from $82.8m. in 2004, the Yehud,-based company said. AudioCodes CEO Shabtai Adlersberg said he expects 2006 to be a year of "growth and increased demand." Shares of AudioCodes fell 3.6 percent, to NIS 57.18 in Tel Aviv. Zoran Corp. halves its net losses Haifa-based Zoran Corp. halved its net losses in 2005 as record revenues were driven by a strong performance in its digital camera and DTV business. Zoran, a chip manufacturer for consumer electronics products, said 2005 brought net losses of $27m., or 61 cents a share, compared to $47.4m., or $1.11 per share, a year earlier. Full year revenues rose to $395.8m., from $378.9m in 2004. Fourth quarter net losses were $2.1m., or five cents per share, from a net profit of $5m. in the parallel 2004 quarter. Revenues for the quarter rose to $109.3m., from $74.8m. in the three months of 2004. NDS net income up 45% in Q2 NDS Group Plc said net profit for its fiscal second quarter ending December 31 rose 45% to $25.9m., or 45 cents per share, from $17.8m., or 32 cents per share a year earlier. The maker of conditional access systems for pay television services said revenues rose 7% to $152m. NDS, which has its main R&D center in Jerusalem, said the rise came through an increase in subscribers and middleware deployments.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS